U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204340) titled 'TLN-372 in Advanced KRAS Mutant Solid Tumors' on Sept. 24.
Brief Summary: The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Study Start Date: Oct. 09
Study Type: INTERVENTIONAL
Condition:
KRAS Mutant Solid Tumors
Intervention:
DRUG: TLN-372
Specified dose on specified days
DRUG: TLN-372 in combination with cetuximab
Specified dose on specified days
DRUG: TLN-372 in combination with pembrolizumab
Specified dose on specified days
Recruitment Sta...